What is Karolinska Development?
Karolinska Development, established in 2003 and headquartered in Stockholm, Sweden, operates as a venture capital firm. The firm's investment thesis centers on providing capital across growth, seed, and early-stage companies, with a pronounced specialization in the life sciences sector. Its portfolio interests span pharmaceutical research, medical research, healthcare technology, gene research, drug delivery technologies, biotechnology, and life science tools. Geographically, Karolinska Development focuses its investments within the Nordic region, encompassing Sweden, Iceland, Norway, Finland, and Denmark. While often taking the lead investor role, the firm also engages in co-investment opportunities, aiming to support up to five new projects annually.
How much funding has Karolinska Development raised?
Karolinska Development has raised a total of $7.4M across 1 funding round:
Debt
$7.4M
Debt (2019): $7.4M with participation from Sino Biopharmaceutical Limited
Key Investors in Karolinska Development
Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited is a significant entity in the pharmaceutical landscape, likely contributing strategic capital and industry expertise to its portfolio companies.
What's next for Karolinska Development?
The recent major strategic investment into Karolinska Development signals a pivotal moment for the firm, likely enabling the expansion of its investment portfolio and the scaling of its operational capabilities. This infusion of capital is expected to fuel further development within the life sciences and healthcare technology sectors, particularly in the Nordic region. The company's continued focus on early-stage and growth-stage ventures suggests a commitment to fostering innovation and supporting the next generation of groundbreaking companies in its specialized fields.
See full Karolinska Development company page
